Skip to main content
OpenTrials
Completed

NCT Number: NCT01289444

Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle

Our goal is to advance palliative care to adolescents and their families. We hope our study will decrease suffering (psychological, spiritual, physical) and increase quality of life (QOL). Left unprepared for end-of-life decisions, miscommunication and disagreements may result in families being charged with neglect or court battles over treatment choices. FAmily CEntered (FACE) Advance Care Planning helps prepare adolescents with HIV/AIDS and their families for future medical decisions. We hope to increase families' understanding of their teens' wishes for end-of-life care and to decrease conflict. We will also study communication and spiritual struggle Families will be randomized into the either the Control (N=65 families) or FACE Intervention (N=65 families). FACE families will meet with a trained/certified researcher for three 60- to 90-minute sessions scheduled one week apart: Session 1: Lyon Advance Care Planning Survey© - Adolescent and Surrogate Versions: Session 2: The Respecting Choices Interview® Session 3: Completion of The Five Wishes©. Control families will also meet with a researcher for three 60-to 90-minute sessions scheduled one week apart: Session 1: Developmental History, Session 2: Safety Tips, and Session 3: Nutrition. Questionnaires will be administered five times, when first seen, at 3, 6, 12 and 18 months from the time of Session 3. Hypothesis 1: Compared to an active control, FACE will relieve psychological suffering by 1) increasing congruence in treatment preferences between teens with AIDS and their surrogates, 2) decreasing decisional conflict regarding EOL decision making for future medical treatment in adolescents with AIDS; 3) increasing quality communication about EOL care in adolescent/legal guardian or surrogate dyads; 4) and maximizing QOL.

Hypothesis 2: In addition to the direct effects, FACE will also indirectly affect QOL through dimensions of threat appraisal.

Hypothesis 3: FACE will have stronger effects on the QOL measures among patients who have less spiritual struggle.

Hypothesis 4: Spiritual struggle has both direct and indirect effects on hospitalization/dialysis use. FACE will also affect hospitalization/dialysis use indirectly through threat appraisal and HAART adherence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's National Medical Center, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

Our goal is to advance palliative care with children and their families aimed at relieving suffering (psychological, spiritual, physical) and maximizing quality of life. Left unprepared for end-of-life decisions, miscommunication and disagreements may result in families being charged with neglect, court battles and even legislative intervention. We propose building on our R34, evidence based model, the Family Centered (FACE) Advance Care Planning intervention, to test our full theoretical model examining the putative mediators and moderators, and spiritual struggle (negative religious coping) with a sicker group and adolescents with AIDS in an adequately powered randomized, clinical, 2-arm, controlled trial. FACE is a culturally sensitive and developmentally appropriate, manualized family intervention based on transactional stress and coping theory, which prepares adolescents with HIV/AIDS and their families for end-of-life decision-making through problem solving. Theoretically, threat appraisal is related to Lazarus' concept of primary appraisal, particularly the way in which an event threatens the child's goals or values. Spiritual struggle (negative religious coping) may be a source of distress, causing disparities in palliative care and outcomes. We will test the efficacy of the FACE intervention for increasing communication and congruence in end-of-life treatment preferences between teens with AIDS and their surrogates, and determine if increased congruence can be maintained over time. We will also examine the impact of the FACE intervention on decisional conflict, quality of communication, and patient quality of life. We will also evaluate hypothesized mediators (threat appraisal, HAART adherence) and moderator (spiritual struggle) of study outcomes, including hospitalizations. We will recruit from hospital-based clinics and randomize 130 adolescent/surrogate dyads (N=260 subjects) to either Control (N=65 dyads) or FACE Intervention (N=65 dyads). Participants with HIV dementia, severe depression, suicidality or homicidality or in foster care will not be allowed to participate. Three 60- to 90-minute sessions will be conducted with a certified interviewer at weekly intervals: FACE: Session 1: Lyon Advance Care Planning Survey© - Adolescent and Surrogate Versions: Session 2: The Respecting Choices Interview® Session 3: Completion of The Five Wishes©. Control will also be administered in a family group format to control for time, attention, and Hawthorn effects: Session 1: Developmental History, Session 2: Safety Tips, and Session 3: Safety Tips. Standardized self-report measures will be administered at baseline, immediate post intervention (3 month), and 6, 12 and 18 month post intervention. Generalized estimating equation (GEE) will assess outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Adolescent Inclusion Criteria:

  • Diagnosed ever with HIV;
  • All ethnic groups;
  • Knows HIV status;
  • Speaks English;
  • Absence of active homicidality or suicidality;
  • Absence of HIV dementia;
  • IQ >69;
  • Consent from the legal guardian for adolescents aged 14-17;
  • Consent from the surrogate for adolescents aged 18-21;
  • Assent from adolescent aged 14-17;
  • Consent from adolescent aged 18-21;
  • Absence of severe depression;
  • Not in foster care

Legal Guardian Inclusion Criteria for Legal Guardians of Adolescents Age 14-17:

  • Adolescent willingness to discuss problems related to HIV/AIDS with them;
  • Age 18 or older;
  • Ability to speak English;
  • Absence of active homicidality, suicidality, or psychosis;
  • Absence of HIV dementia;
  • Legal guardian;
  • Consent to participate; Consent for his/her adolescent to participate;
  • Knows HIV status of adolescent;
  • Absence of depression in the severe range;

Surrogate Inclusion Criteria for Adolescents Age 18-21:

  • Selected by adolescent aged 18 to 21;
  • Age 18 or older;
  • Willingness to discuss problems related to HIV and end-of-life;
  • Absence of active homicidality, suicidality, or psychosis;
  • Absence of HIV dementia;
  • Speaks English;
  • Consent to participate;
  • Knows HIV status of adolescent.
  • Absence of severe depression;

Exclusion criteria

  • adolescent or surrogate does not know HIV diagnosis
  • being in foster care
  • developmentally delayed
  • scoring below the cut off on the HIV Dementia Scale
  • scoring above the cut off for depressive symptoms on the Beck Depression Inventory
  • homicidal, suicidal or psychotic on screening
  • does not speak English

Treatment and study plan

FAmily CEntered (FACE) ACP

Behavioral

Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.

Other names: FACE

Healthy Living Control

Behavioral

Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.

  • Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides.

Other names: HLC

Primary outcomes

  1. congruence in treatment preferences

    Time frame: Change from baseline in Congruence in Treatment Preferences at 18 months post-intervention compared to control

    Measured by the Statement of Treatment Preferences

Secondary outcomes

  1. QOL

    Time frame: Change from baseline in Quality of Life at 18 months post-intervention compared to control

    Measured by score on Varni's Peds QoL

  2. Utilization of hospitalization

    Time frame: Change from baseline in hospitalizations at 18 month follow-up post intervention compared to control

    Hospitalization will be measured by chart review. Each site has hospital based services for patient population

  3. Utilization of dialysis

    Time frame: Change from baseline in use of dialysis at 18 month post-intervention compared to control

    Use of dialysis will be measured by chart review.

Sponsors and collaborators

Lead sponsor

Maureen Lyon

Other

Collaborators

  • Broward Health
  • Howard University
  • Johns Hopkins University
  • St. Jude Children's Research Hospital
  • University of Miami

Registry information

Acronym: FACE

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Feb 3, 2011
Registry last updated
Oct 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.